

Coronavirus Covid-19 Testing: Symptoms, Asymptomatic, and Serology for Immunity

https://marketpublishers.com/r/CB23DBD8FCE2EN.html

Date: April 2020

Pages: 98

Price: US\$ 4,500.00 (Single User License)

ID: CB23DBD8FCE2EN

Abstracts

LEXINGTON, Massachusetts (April 3, 2020) – WinterGreen Research announces that it has a new study available that describes United States testing for the rapidly evolving COVID-19 pandemic. Testing capability forecasts for PCR assay and Molecular Diagnostics are presented in two week increments for the next 6 months. Availability of Serological testing is also forecast for detection of the virus after recovery.

All major vendors are included and can be compared with quantities, qualities, and test time. Covid-19 Testing 2020: The Way Forward describes the timelines the virus is likely to take regarding quarantines and successive waves of infection. Successive waves of infection are expected to strike the US population after the shelter in place restrictions start to be lifted. Intensive testing is needed at every stage of covid-19 disease management. The testing scenarios and the vendors with good test kits are described in detail.

Successive waves of infection are expected to continue to at least January 2021. One thing that will stop them is if effective vaccine is found. The 2020 study has 96 pages, 12 tables and figures. The tables describe in enormous detail what testing kits are available and the significance of further testing. It describes testing capacity and length of time to administer testing. It describes the impact of testing and the need for serological testing as the quarantines begin to end.

PCR testing – as used by the CDC and WHO initially – is very labor intensive, and has several points along the path of doing a single test where errors may occur – which may lead to headline issues of a false positive, the test showing evidence of the virus when it's not actually there, or a false negative, suggesting someone doesn't have the virus when in fact they do.



The virus and the resulting disease, Covid-19, have hit Germany with force: According to Johns Hopkins University, the country had more than 91,000 laboratory-confirmed infections by Saturday morning, more than any other country except the United States, Italy and Spain. But with 1,275 deaths, Germany's fatality rate stood at 1.3 percent, compared with 12 percent in Italy, around 10 percent in Spain, France and Britain, 4 percent in China and 2.5 percent in the United States. Even South Korea, a model of flattening the curve, has a higher fatality rate, 1.7 percent.

When the first cases of COVID-19 were reported in the US, two labs at the CDC were the only ones permitted to conduct COVID-19 testing, using a test developed by the agency's own researchers. When the CDC tried to expand testing by providing its test kits to state and local public health labs, there were problems with the initial version of the kits, The CDC, despite initially faulty reagents making its first test kits unreliable, is now offering accurate RT-PCR Diagnostic Panels and positive and human specimen controls.

"Had {the US} done more testing from the very beginning and caught cases earlier," said Dr. Nuzzo, of Johns Hopkins, "we would be in a far different place."

WinterGreen Research is an independent research organization funded by the sale of market research studies all over the world and by identifying next generation technology. It is next generation technology that drives market growth. The company has 35 distributors worldwide, including Global Information Info Shop, Market Research.com, Research and Markets, Report Linker

WinterGreen Research is positioned to help customers facing challenges that define the modern enterprises. The increasingly global nature of science, technology and engineering is a reflection of the implementation of the globally integrated enterprise. Customers trust WinterGreen Research to work alongside them to ensure the success of the participation in a particular market segment.

WinterGreen Research supports various market segment programs; provides trusted technical services to the marketing departments. It carries out accurate market share and forecast analysis services for a range of commercial and government customers globally. These are all vital market research support solutions requiring trust and integrity.



Contents

ABSTRACT: COVID-19 TESTING PATIENTS WITH SYMPTOMS, PATIENTS WITH NO SYMPTOMS AND SEROLOGY TESTING FOR IMMUNITY AND QUARANTINE AVOIDANCE

COVID-19 TESTING IN THE US: EXECUTIVE SUMMARY

Testing and Covid-19
PCR Testing for Covid-19
Serological Testing for Covid-19

1. US COVID-19 TESTING - CDC AND VENDOR ABILITY TO PROVIDE TESTS

- 1.1 Covid-19 PCR Testing Market Driving Forces
- 1.2 Covid-19 Testing
- 1.3 Covid-19 Testing Equipment Missed the Mark
 - 1.3.1 Covid-19 Need for Quarantine
 - 1.3.2 Viral Load
 - 1.3.3 Covid-19 Testing on Patients with Symptoms
 - 1.3.4 Covid-19 Serological Contact Testing
 - 1.3.5 Covid-19 Serological Testing on Social Contacts of Patients with Symptoms
- 1.4 Covid-19 Testing Prices

2. DELAYS IN US COVID-19 TESTING AND INTERNATIONAL RESPONSE

- 2.1 Broader Testing Delayed
- 2.2 Government and Open Market Control of Testing
- 2.3 Extracting Virus from Blood Sample

3. COVID-19 TESTING REGIONAL ANALYSIS

- 3.1 Covid-19 Number People Affected Worldwide
- 3.2 US
- 3.3 China
- 3.4 India
- 3.5 Europe
- 3.6 Asia
- 3.7 Rest of World



4. COVID-19 MOLECULAR DIAGNOSTICS TESTING TECHNOLOGY

- 4.1 Coronavirus Assay Testing Technique Polymerase Chain Reaction (PCR)
- 4.2 Panther Fusion Automates The Complex Steps Involved In Molecular Diagnostics Covid-19 Testing
 - 4.2.1 Molecular Diagnostics
- 4.3 Scientists Need The Actual Virus In Order To Check A Diagnostic Test

5. COVID-19 TESTING EQUIPMENT COMPANY PROFILES

- 5.1 Abbott Laboratories
- 5.2 Alphabet Verify
- 5.3 Astrotech
- 5.4 Beckman Coulter
- 5.5 Bill Gates
- 5.6 bioM?rieux
- 5.7 Bodysphere
- 5.8 Center for Disease Control and Prevention CDC
 - 5.8.1 CDC Serology Test for SARS-CoV-2
- 5.9 Co-Diagnostics, Inc.
- 5.10 Danaher
 - 5.10.1 Cepheid is part of Danaher (NYSE:DHR).
 - 5.10.2 Cepheid
 - 5.10.3 Danaher/Integrated DNA Technologies (IDT)
- 5.11 US FDA
- 5.12 GenMark Diagnostics
- 5.13 Hologic
- 5.14 Hong Kong University of Science and Technology (HKUST)
- 5.15 LabCorp
 - 5.15.1 LabCorp Testing
- 5.16 Logix Smart
- 5.17 Mammoth Biosciences
- 5.18 Opko/BioReference Laboratories
 - 5.18.1 OPKO Health
- 5.19 Quidel
- 5.20 Quest Diagnostics
- 5.20.1 Quest/Roche Partnership
- 5.20.2 Roche IVD test/Quest Diagnostics LDT



- 5.21 Roche Diagnostics
 - 5.21.1 Roche IVD Test for COVID-19 Offered by Quest Diagnostics
- 5.22 Sherlock Biosciences
- 5.23 SunSure Biotech
- 5.24 Tianjin University China
- 5.25 Thermo Fisher Scientific
 - 5.25.1 Thermo Fisher Scientific/Applied Biosystems
 - 5.25.2 Thermo Fisher/Dutch Diagnostics Firm Qiagen
- 5.26 Tianjin University of China.
- 5.27 Where to Look for More Covid-19 Information

6. COVID-19 PCR TESTING: DESCRIPTION AND DYNAMICS

- 6.1 Rapidly Evolving COVID-19
- 6.2 COVID-19 a Respiratory Illness
 - 6.2.1 Covid-19 Symptoms
 - 6.2.2 Diagnostic Testing for COVID-19
 - 6.2.3 Guidance for Testing
 - 6.2.4 Covid-19 Quarantine
- 6.3 PCR and Molecular Diagnostic Testing Status
- 6.4 Where to get Tested
- 6.5 Testing: False Negative and False Positive
- 6.6 Serology Testing for COVID-19

WINTERGREEN RESEARCH,

WinterGreen Research Methodology

WinterGreen Research Process

Market Research Study

WinterGreen Research Global Market Intelligence Company

Report Description: Revenue Models Matter



List Of Figures

LIST OF FIGURES

Abstract: Covid-19 Testing Patients with Symptoms, Patients with No Symptoms and Serology Testing for Immunity and Quarantine Avoidance

Figure 1. US Covid-19 Serological Testing to see if a Person Has Already Had the

Corona Virus and Does Not Need to Be Put in Quarantine, April 1 2020 to

September 1, 2020 Capability Forecasts by Two Week Intervals

Figure 2. US Serological Testing on People Who Have Been in Contact with Covid-19

Patients with Symptoms, May 1 to October 1, 2020

Figure 3. Covid-19 US Testing Market Driving Forces

Figure 4. Covid-19 Testing for Quarantine Implementation

Figure 5. CDC and Vendor implementation of Covid-19 Testing

Figure 6. Testing in the Next Phase of COVID-19 Outbreak: Suppression

Figure 7. Covid-19 Characteristics Impacted by Testing

Figure 8. Testing Characteristics Impacting Covid-19 Healthcare Management23

Figure 9. Covid-19 Testing Initially Quarantined Population Management Timelines24

Figure 10. Covid-19 Testing Second Wave Quarantined Population Management Timelines

Figure 11. Impact on Testing of Waves of Critically III Patients with Covid-19

Figure 12. US Covid-19 Testing Equipment Market Share Description, Number of

Tests Day, Tests per Week Capability, Time to Administer, April 1, 2020

Figure 13. US Covid-19 Testing Equipment Company Description, Number of Tests per

Day, Tests per Week Capability, April 1, 2020, Time to Administer, April 1, 2020

Figure 14. US Covid-19 Patient with Symptom Testing Capability April 1 2020 to

September 1, 2020 Forecasts by Two Week Intervals, Testing Patients Who Present Symptoms at Care Facility or Hospital

Figure 15. US Serological Testing on People Who Have Been in Contact with Covid-19

Patients with Symptoms, May 1 to October 1, 2020

, , , , , ,

Figure 16. Abbott Virus Detection Machine

Figure 17. GenMark Diagnostics Coronavirus ePlex Testing System

Figure 18. Hologic's Panther Fusion® SARS-CoV-2 test

Figure 19. Quest Healthcare Provider Fact Sheet

Figure 20. Governor Cuomo - The Face of COVID-19 Resistance



I would like to order

Product name: Coronavirus Covid-19 Testing: Symptoms, Asymptomatic, and Serology for Immunity

Product link: https://marketpublishers.com/r/CB23DBD8FCE2EN.html

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CB23DBD8FCE2EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| First name: | |
|---------------|---------------------------|
| Last name: | |
| Email: | |
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970